Lorlatinib latest price in 2024

Lorlatinib (Lorlatinib) is a targeted therapy drug that belongs to ALK (tyrosine kinase) and ROS1 (ROS1kinase) inhibitors, mainly used to treat ALK and ROS1 positive non-small cell lung cancer (NSCLC).

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. Please consult the local hospital pharmacy for details. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

As a new generation of targeted drugs, lorlatinib has shown excellent efficacy in patients with NSCLC targeting ALK and ROS1 mutations. Its unique feature is that it can simultaneously inhibit multiple ALK and ROS1 fusion gene variants, which has important therapeutic significance for patients who are resistant to other ALK inhibitors.

The molecular structure and mechanism of action of lorlatinib make it highly selective and able to block abnormally activated ALK and ROS1 signaling pathways, thereby inhibiting the growth and spread of cancer cells. This is an innovative and effective treatment option for ALK and ROS1 positive NSCLC patients.

In clinical trials, lorlatinib demonstrated good tolerability and efficacy. After receiving treatment, patients have shown significant tumor shrinkage and disease stabilization in some cases, providing hope and new treatment prospects for this specific subgroup of patients.

However, as with any drug, lorlatinib may cause some side effects, including but not limited to nausea, fatigue, high blood pressure, etc. Therefore, when using lorlatinib, patients need to be under the supervision of a doctor and undergo regular examinations to monitor the efficacy of the treatment and the patient's overall health.